| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Institut de Biochimie Clinique, and Institut d'Histologie et d'Embryologie, Université de Genève, Geneva, Switzerland
Abstract
The effects of somatostatin (SRIF) on glucagon release have been studied in the monolayer culture of newborn rat pancreas. It was found that SRIF inhibited glucagon release rapidly and in a dose dependent manner at concentrations of 1–1000 ng/ml. SRIF inhibited glucagon release under basal conditions and after stimulation by arginine, 3-isobutyl-l-methylxanthine (IBMX), high Ca++ concentrations, ionophore A23187 and Ca++, and Ba++. SRIF inhibited ionophore- induced glucagon release over 60 min when a low concentration of A23187 was used (0.1 µg/ml) but not when a high concentration (10 µg/ml) was used. The stimulant effect of 10 µg/ml A23187 was, however, inhibited by SRIF during short periods of incubation. The per cent inhibition of argininestimulated glucagon release due to SRIF remained unchanged when the Ca++ concentration in the medium was varied from 1–10 mM.
It is concluded that SRIF promptly inhibits glucagon release under basal conditions or when stimulated by a variety of agents. Thus, the action of SRIF appears to be basic to the granule release process and not specifically antagonistic to any particular stimulants. Further, as SRIF inhibits release due to raised cytosol Ca++ (e.g., ionophore- Ca++ or high Ca++ experiments) the action is probably at a late point in the release mechanism.
Footnotes
Supported by the Swiss National Science Foundation kraut nos. 3.1060.73, 3.0280.73 and 3.553.75).
Received February 2, 1977.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |